|
Berger, Alice H; Niki, Masaru; Morotti, Alessandro et al. (2010) Identification of DOK genes as lung tumor suppressors. Nat Genet 42:216-23
|
|
Rossi, Ferdinand; Yozgat, Yasemin; de Stanchina, Elisa et al. (2010) Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib. Mol Cancer Res 8:1271-83
|
|
Guo, Tianhua; Hajdu, Mihai; Agaram, Narasimhan P et al. (2009) Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KITAY502-3ins mutation: an in vitro mutagenesis screen for drug resistance. Clin Cancer Res 15:6862-70
|
|
Antczak, Christophe; Veach, Darren R; Ramirez, Christina N et al. (2009) Structure-activity relationships of 6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)pyrido[2,3-d]pyrimidin-7-ones: toward selective Abl inhibitors. Bioorg Med Chem Lett 19:6872-6
|
|
Kashiwada, Masaki; Cattoretti, Giorgio; McKeag, Lisa et al. (2006) Downstream of tyrosine kinases-1 and Src homology 2-containing inositol 5'-phosphatase are required for regulation of CD4+CD25+ T cell development. J Immunol 176:3958-65
|
|
Liang, Xiquan; Hajivandi, Mahbod; Veach, Darren et al. (2006) Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells. Proteomics 6:4554-64
|
|
Janas, Justyna; Skowronski, Jacek; Van Aelst, Linda (2006) Lentiviral delivery of RNAi in hippocampal neurons. Methods Enzymol 406:593-605
|
|
Zhao, Mingming; Janas, Justyna A; Niki, Masaru et al. (2006) Dok-1 independently attenuates Ras/mitogen-activated protein kinase and Src/c-myc pathways to inhibit platelet-derived growth factor-induced mitogenesis. Mol Cell Biol 26:2479-89
|
|
Oki, Shinji; Limnander, Andre; Yao, Pin Mei et al. (2005) Dok1 and SHIP act as negative regulators of v-Abl-induced pre-B cell transformation, proliferation and Ras/Erk activation. Cell Cycle 4:310-4
|
|
Wolff, Nicholas C; Veach, Darren R; Tong, William P et al. (2005) PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood 105:3995-4003
|
Showing the most recent 10 out of 37 publications
